CN110973630A - Composition for resisting intestinal aging and application thereof - Google Patents
Composition for resisting intestinal aging and application thereof Download PDFInfo
- Publication number
- CN110973630A CN110973630A CN201911324100.9A CN201911324100A CN110973630A CN 110973630 A CN110973630 A CN 110973630A CN 201911324100 A CN201911324100 A CN 201911324100A CN 110973630 A CN110973630 A CN 110973630A
- Authority
- CN
- China
- Prior art keywords
- composition
- percent
- intestinal
- mass
- aging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 78
- 230000000968 intestinal effect Effects 0.000 title abstract description 50
- 230000032683 aging Effects 0.000 title abstract description 32
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims abstract description 20
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims abstract description 20
- 229920002079 Ellagic acid Polymers 0.000 claims abstract description 20
- 235000004132 ellagic acid Nutrition 0.000 claims abstract description 20
- 229960002852 ellagic acid Drugs 0.000 claims abstract description 20
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims abstract description 20
- 235000012055 fruits and vegetables Nutrition 0.000 claims abstract description 18
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims abstract description 14
- 239000000600 sorbitol Substances 0.000 claims abstract description 14
- 239000000463 material Substances 0.000 claims abstract description 13
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 13
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 13
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 11
- 235000013325 dietary fiber Nutrition 0.000 claims abstract description 9
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 claims description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 16
- 239000000843 powder Substances 0.000 claims description 15
- 102000016942 Elastin Human genes 0.000 claims description 14
- 108010014258 Elastin Proteins 0.000 claims description 14
- 229920001100 Polydextrose Polymers 0.000 claims description 14
- 229920002549 elastin Polymers 0.000 claims description 14
- 239000001259 polydextrose Substances 0.000 claims description 14
- 235000013856 polydextrose Nutrition 0.000 claims description 14
- 229940035035 polydextrose Drugs 0.000 claims description 14
- 244000000626 Daucus carota Species 0.000 claims description 13
- 229920001353 Dextrin Polymers 0.000 claims description 13
- 239000004375 Dextrin Substances 0.000 claims description 13
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 13
- 235000005770 birds nest Nutrition 0.000 claims description 13
- 235000019425 dextrin Nutrition 0.000 claims description 13
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 13
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 13
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 13
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 13
- 235000005765 wild carrot Nutrition 0.000 claims description 13
- 230000003712 anti-aging effect Effects 0.000 claims description 12
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 12
- 239000012141 concentrate Substances 0.000 claims description 8
- 244000078534 Vaccinium myrtillus Species 0.000 claims description 6
- 244000068988 Glycine max Species 0.000 claims description 3
- 235000010469 Glycine max Nutrition 0.000 claims description 3
- 244000294611 Punica granatum Species 0.000 claims description 3
- 235000014360 Punica granatum Nutrition 0.000 claims description 3
- 240000007651 Rubus glaucus Species 0.000 claims description 3
- 235000011034 Rubus glaucus Nutrition 0.000 claims description 3
- 235000009122 Rubus idaeus Nutrition 0.000 claims description 3
- 235000003095 Vaccinium corymbosum Nutrition 0.000 claims description 3
- 235000017537 Vaccinium myrtillus Nutrition 0.000 claims description 3
- 235000021014 blueberries Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 244000099147 Ananas comosus Species 0.000 claims description 2
- 235000007119 Ananas comosus Nutrition 0.000 claims description 2
- 235000009467 Carica papaya Nutrition 0.000 claims description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 2
- 235000021307 Triticum Nutrition 0.000 claims description 2
- 244000098338 Triticum aestivum Species 0.000 claims description 2
- 240000008042 Zea mays Species 0.000 claims description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims description 2
- 235000021329 brown rice Nutrition 0.000 claims description 2
- 235000005822 corn Nutrition 0.000 claims description 2
- 240000006432 Carica papaya Species 0.000 claims 1
- 229920002774 Maltodextrin Polymers 0.000 claims 1
- 239000005913 Maltodextrin Substances 0.000 claims 1
- 229940035034 maltodextrin Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 25
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 abstract description 14
- 102000019197 Superoxide Dismutase Human genes 0.000 abstract description 14
- 108010012715 Superoxide dismutase Proteins 0.000 abstract description 14
- 229940118019 malondialdehyde Drugs 0.000 abstract description 14
- 239000002994 raw material Substances 0.000 abstract description 9
- 102000006587 Glutathione peroxidase Human genes 0.000 abstract description 7
- 108700016172 Glutathione peroxidases Proteins 0.000 abstract description 7
- 230000003078 antioxidant effect Effects 0.000 abstract description 6
- 230000002708 enhancing effect Effects 0.000 abstract description 4
- 235000013376 functional food Nutrition 0.000 abstract description 4
- 241000699670 Mus sp. Species 0.000 description 19
- 241000894006 Bacteria Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 11
- 239000000126 substance Substances 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 244000052616 bacterial pathogen Species 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 210000005228 liver tissue Anatomy 0.000 description 6
- 208000036649 Dysbacteriosis Diseases 0.000 description 5
- 208000027244 Dysbiosis Diseases 0.000 description 5
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 230000007140 dysbiosis Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 4
- 238000011579 SCID mouse model Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 229930003270 Vitamin B Natural products 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 244000005709 gut microbiome Species 0.000 description 3
- 210000000936 intestine Anatomy 0.000 description 3
- 239000006041 probiotic Substances 0.000 description 3
- 235000018291 probiotics Nutrition 0.000 description 3
- 230000009758 senescence Effects 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011720 vitamin B Substances 0.000 description 3
- 235000019156 vitamin B Nutrition 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229960000282 metronidazole Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 244000189799 Asimina triloba Species 0.000 description 1
- 235000006264 Asimina triloba Nutrition 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 241000269851 Sarda sarda Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 241001506047 Tremella Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- RQFQJYYMBWVMQG-IXDPLRRUSA-N chitotriose Chemical compound O[C@@H]1[C@@H](N)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](N)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)[C@@H](CO)O1 RQFQJYYMBWVMQG-IXDPLRRUSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000007760 free radical scavenging Effects 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000007413 intestinal health Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100001252 long-term toxicity Toxicity 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150100211 nutA gene Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000384 rearing effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
- A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Botany (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An anti-intestinal aging composition and application thereof, relating to the field of functional food. The composition for resisting intestinal aging comprises the following components in percentage by mass: ellagic acid 5-10%, vitamin B60.001-0.01 percent, 5-10 percent of fruit and vegetable leavening, 10-20 percent of sorbitol, 20-40 percent of oligosaccharide, 5-20 percent of water-soluble dietary fiber and 0-20 percent of auxiliary material. The raw materials are mixedThe composition of the intestinal flora is effectively reduced, the composition of the intestinal flora is adjusted, the diversity of the intestinal flora is promoted, the glutathione peroxidase activity and the superoxide dismutase activity of a host are further improved, the malondialdehyde content is reduced, and the aims of enhancing the intestinal antioxidant activity and delaying the intestinal aging are fulfilled.
Description
Technical Field
The application relates to the field of functional foods, in particular to an anti-intestinal-aging composition and application thereof.
Background
With the recent intense research on the gut microbiome, a new consensus has been reached: aging of the intestinal tract is closely related to the change of the diversity of the intestinal flora.
The symbiotic relationship of gut microbes and hosts is called a "super organism". When the intestine begins to age, its immune response increases dramatically and becomes chronically generalized throughout the body, and this chronic immune activation is closely related to age-related diseases. Aging is very closely linked to changes in the intestinal microflora, with increasing age, the number of intestinal probiotics decreases gradually, and the composition and diversity of the intestinal microflora decreases. And imbalance of intestinal flora can lead to growth of putrefactive harmful flora (LPS producing bacteria), increase of toxin secretion and promote aging process.
In view of this, the present application is hereby presented.
Disclosure of Invention
The present application provides an anti-aging composition for the intestine and the application thereof, in order to improve the technical problems.
According to the embodiment of the first aspect of the application, the composition for resisting intestinal aging comprises the following components in percentage by mass:
ellagic acid 5-10%, vitamin B60.001-0.01 percent, 5-10 percent of fruit and vegetable leavening, 10-20 percent of sorbitol, 20-40 percent of oligosaccharide, 5-20 percent of water-soluble dietary fiber and 0-20 percent of auxiliary material.
According to the composition for resisting intestinal aging, by matching the raw materials, harmful intestinal bacteria (LPS producing bacteria) are effectively reduced, the composition of intestinal flora is adjusted, the diversity of the intestinal flora is promoted, the activity of glutathione peroxidase (GSH-PX) and the activity of superoxide dismutase (SOD) of a host are further improved, the content of Malondialdehyde (MDA) is reduced, and the purposes of enhancing the antioxidant activity of the intestinal tract and delaying the intestinal aging are achieved.
Use of the above-described anti-gut aging composition according to embodiments of the second aspect of the present application in an anti-gut aging product.
The application of the anti-intestinal-aging composition in the preparation of the anti-intestinal-aging product according to the second aspect of the application has the effects of reducing intestinal harmful bacteria (LPS-producing bacteria) and assisting in anti-intestinal-aging by using the anti-intestinal-aging composition provided by the first aspect of the embodiment.
Detailed Description
In order to make the objects, technical solutions and advantages of the embodiments of the present application clearer, the technical solutions of the embodiments of the present application will be clearly and completely described below. The examples, in which specific conditions are not specified, were conducted under conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used are not indicated by the manufacturer, and are all conventional products available commercially.
The anti-aging composition and the use thereof according to the embodiments of the present application will be described in detail below.
The application provides an anti-intestinal-aging composition, which comprises the following components in percentage by mass:
ellagic acid 5-10%, vitamin B60.001-0.01 percent, 5-10 percent of fruit and vegetable leavening, 10-20 percent of sorbitol, 20-40 percent of oligosaccharide, 5-20 percent of water-soluble dietary fiber and 0-20 percent of auxiliary material.
According to the composition for resisting intestinal aging, the raw materials are reasonably mixed and act together, so that harmful intestinal bacteria (LPS producing bacteria) are effectively reduced, the composition of intestinal flora is adjusted, the intestinal aging is assisted to strengthen the anti-aging effect of a human body, the activity of glutathione peroxidase (GSH-PX) and the activity of superoxide dismutase (SOD) of a host are improved, the content of Malondialdehyde (MDA) is reduced, and the aims of strengthening the anti-oxidation activity of the intestinal tract and delaying the intestinal aging are further fulfilled.
Wherein ellagic acid is widely present in plant tissues such as soft fruit and nutA natural polyphenol fraction has strong free radical scavenging and antioxidant effects, and is therefore commonly used for skin whitening. In this application, ellagic acid and vitamin B are used6And the reasonable compatibility of the rest raw materials effectively adjusts the composition and diversity of the intestinal flora and inhibits the growth of LPS producing bacteria.
In the actual use process, the ellagic acid can be provided by a purified ellagic acid product, or can be provided by pomegranate concentrated powder, blackberry concentrated powder, raspberry concentrated powder, blueberry concentrated powder and the like which are rich in ellagic acid, as long as the ellagic acid contained in the ellagic acid reaches the range required by the application. Thus, the ellagic acid is provided by at least one of pomegranate concentrate powder, blackberry concentrate powder, raspberry concentrate powder, and blueberry concentrate powder.
The fruit and vegetable fermented product combines the characteristics of the fruit and vegetable raw materials and compatibility, basically keeps the original content of various vitamins and minerals (such as vitamin C, vitamin B group, calcium, iron, zinc, copper and the like) in the fruits and vegetables, is used as a beneficial supplement for the intake of micronutrients, regulates the intestinal health and the body metabolism, and maintains the normal physiological function.
In the embodiment provided by the application, the fruit and vegetable fermented product is prepared by mixing pawpaw, pineapple, corn, soybean, wheat, brown rice, millet and the like, inoculating yeast and fermenting. Under the conditions, the nutrient substances required by intestinal flora are effectively supplemented, the diversity of the intestinal flora is promoted, the fermentation is convenient to absorb, and the intestinal burden is reduced. The proportion, fermentation time and mode of the raw materials of the fruit and vegetable fermented product can be carried out according to actual requirements by referring to related technologies, and are not described herein, and besides, the fruit and vegetable fermented product can also be directly purchased from the market.
The addition of sorbitol can effectively adjust the intestinal environment, and the sorbitol and the vitamin B are reasonably mixed6And oligosaccharide, etc. to promote the growth of probiotics, lower intestinal pH, inhibit the growth of LPS producing bacteria and toxin secretion, and resist intestinal tract senility. At the same time, sorbitol hasHas a certain sweetness, and can improve the mouthfeel of the composition for resisting intestinal aging.
The regulation of intestinal flora by oligosaccharide is mainly characterized by proliferating beneficial bacteria, especially bifidobacterium, and inhibiting harmful bacteria to improve the health level. Wherein the oligosaccharide includes but is not limited to at least one of isomaltooligosaccharide, galactooligosaccharide, stachyose, xylooligosaccharide, soybean oligosaccharide, chitosan oligosaccharide and mannooligosaccharide.
However, the specific action of different oligosaccharides is different, and the regulation effect on different probiotics is different, in this embodiment, in order to inhibit LPS producing bacteria and promote the diversity of beneficial bacteria, in the embodiment provided by the present application, the oligosaccharides are composed of isomaltooligosaccharide, galactooligosaccharide and stachyose, wherein the addition amount of isomaltooligosaccharide is 10% to 20% of the mass of the composition, the addition amount of galactooligosaccharide is 5% to 10% of the mass of the composition, and the addition amount of stachyose is 5% to 10% of the mass of the composition.
The water-soluble dietary fiber can promote intestinal peristalsis, dilute and accelerate the excretion speed of toxic substances, and improve the intestinal flora structure under the combined action of oligosaccharide and the like.
The water-soluble dietary fiber includes, but is not limited to, at least one of resistant dextrin and polydextrose, for example, all of which are resistant dextrin or polydextrose, and may be a mixture of both.
Optionally, in order to optimize the anti-aging effect of the intestine, the water-soluble dietary fiber consists of resistant dextrin and polydextrose, wherein the resistant dextrin is added in an amount of 5-10% by mass of the composition, and the polydextrose is added in an amount of 5-10% by mass of the composition.
The type of the auxiliary materials is not particularly limited, and is mainly used for adjusting the taste, and functional foods or food auxiliary materials well known in the art can be adopted, such as water, polypeptide, cubilose, tremella, honey, fruits, grains, vegetables and the like.
Wherein, optionally, the addition amount of the auxiliary materials in the composition for resisting intestinal aging is 0.1-20% by mass percent. Further optionally, the additive amount of the auxiliary material in the composition for resisting intestinal aging is 5-20%, and further optionally, the additive amount of the auxiliary material in the composition for resisting intestinal aging is 10-20%.
Optionally, the auxiliary material comprises at least one of elastin peptide and bird's nest, for example, the auxiliary material is elastin peptide or bird's nest, or a mixture of the two.
In some embodiments provided herein, optionally, the auxiliary material comprises elastin peptide and bird's nest, which is effective in improving taste, wherein the elastin peptide is added in an amount of 5% -10% of the composition by mass, the bird's nest is added in an amount of 5% -15% of the composition by mass, and the sum of the two cannot exceed 20% of the composition by mass. Among them, there are various elastin peptides, for example, in the examples provided in the present application, the elastin peptide is specifically bonito elastin peptide, and the bird's nest is brewing type bird's nest, which effectively improves the taste.
The composition for resisting intestinal aging can be prepared by directly mixing the raw materials according to a ratio, or can be prepared into solid oral compositions such as powder, granules, capsules and the like by adopting related technologies and equipment, or can be prepared into liquid oral compositions. The way of making it into powder is, for example: the raw material powders are obtained and mixed, and the operation is convenient.
Finally, the application provides the use of the above anti-aging composition in an anti-aging preparation. Wherein, it should be noted that the anti-aging product for intestinal tract may be composed of the above-mentioned anti-aging composition for intestinal tract, or may be added with other raw materials available in the field of functional food, and will not be described in detail herein.
The features and properties of the present application are described in further detail below with reference to examples.
Example 1
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 6.67%, vitamin B60.01 percent of fruit and vegetable leavening, 6.67 percent of sorbitol, 20 percent of isomaltose hypgather, 6.67 percent of galacto-oligosaccharide, 6.67 percent of stachyose, 6.67 percent of resistant dextrin and 6.67 percent of polydextrose; elastin peptide 6.67%, bird's nest 13.3%％。
Example 2
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 8%, vitamin B60.01 percent of fruit and vegetable leavening, 10 percent of sorbitol, 15 percent of isomaltose hypgather, 10 percent of galactooligosaccharide, 8.5 percent of stachyose, 10 percent of resistant dextrin and 7 percent of polydextrose; 5% of elastin peptide and 6.49% of edible bird's nest.
Example 3
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 5%, vitamin B60.01 percent of fruit and vegetable leavening, 10 percent of sorbitol, 20 percent of isomaltose hypgather, 5 percent of galactooligosaccharide, 5 percent of stachyose, 5.99 percent of resistant paste and 10 percent of polydextrose; 10% of elastin peptide and 10% of edible bird's nest.
Example 4
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 9%, vitamin B60.005%, 7% of fruit and vegetable fermented product, 13% of sorbitol, 20% of isomaltooligosaccharide, 9% of galactooligosaccharide, 9% of stachyose, 10% of resistant dextrin and 9% of polydextrose; elastin peptide 6.995%, bird's nest 7%.
Example 5
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 10%, vitamin B60.005 percent, 10 percent of fruit and vegetable leavening, 19.995 percent of sorbitol, 20 percent of isomaltose hypgather, 10 percent of galacto-oligosaccharide, 10 percent of stachyose, 10 percent of resistant dextrin and 10 percent of polydextrose.
Example 6
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 9%, vitamin B60.005 percent of fruit and vegetable leavening, 10 percent of sorbitol 19.995 percent, 18 percent of isomaltooligosaccharide, 10 percent of galactooligosaccharide, 10 percent of stachyose, 9 percent of resistant dextrin, 10 percent of polydextrose and elasticity5% of protein peptide.
Example 7
An anti-intestinal-aging composition comprises the following components in percentage by mass:
ellagic acid 9%, vitamin B60.005%, 10% of fruit and vegetable fermented product, 19.995% of sorbitol, 18% of isomaltose hypgather, 10% of galactooligosaccharide, 10% of stachyose, 9% of resistant dextrin, 10% of polydextrose and 5% of cubilose.
Example 8
An anti-aging product comprising the anti-aging composition of any one of examples 1 to 7 in a weight ratio of 1:1 and water, mixed to make a drink.
Test example 1
1. Acute toxicity test in small animals
1) The substance to be tested: the composition provided in example 1 of the present application was stored at 4 ℃ until use.
2) Test animals: NOD/SCID mice (SPF grade) with a body weight of 22-26 g, male and female halves, provided by Nanjing university.
Number of use license: SYXK 2014-0023.
3) The method and the result are as follows: 48 mice were divided into 4 groups of 12 mice each. Before the test, fasting/water deprivation is carried out for 6 hours, oral dosage is 0.2g/mL, gastric lavage is carried out for 0.2g, 0.4g, 0.6g and 0.8g within 24 hours according to A, B, C, D groups respectively, and observation is carried out for 1 week, wherein NOD/SCID mice have normal activity, no abnormal general state and no observable toxic reaction. It was found that the maximum dose of 40g/kg in terms of body weight was still within the safe range.
2. Long term toxicity test in small animals
1) The substance to be tested: the composition provided in example 1 of the present application was stored at 4 ℃ until use.
2) Test animals: NOD/SCID mice (SPF grade) with a body weight of 22-26 g, male and female halves, provided by Nanjing university.
Number of use license: SYXK 2014-0023.
3) The method and the result are as follows: 48 mice were divided into 4 groups of 12 mice each. Fasting and water prohibition are carried out for 6 hours before the test, the oral dosage is 0.2g/mL, the stomach is gavaged within 24 hours according to A, B, C groups, 0.1g, 0.2g and 0.3g are respectively gavaged within 24 hours, the group D is normally fed as a control group, after continuous feeding for 8 weeks, euthanasia is carried out at the end point of the test, a tissue sample is taken and observed; during the period, NOD/SCID mice normally move, the general state is not abnormal, and the tissue observation results are as follows: compared with the control group, the gavage group has no obvious change and no observable toxic reaction.
The dosage range obtained by weight conversion is still within the safe range relative to the clinical dosage of 60-120 times.
Test example 2
1. The antioxidant index is as follows: glutathione peroxidase (GSH-PX) activity, superoxide dismutase (SOD) activity, and Malondialdehyde (MDA) content.
1) The substance to be tested: the composition prepared according to example 1 was stored at 4 ℃ until use.
2) Test animals: ICR mice (SPF grade) with a body weight of 24-28 g, male and female halves, provided by Witonglihua. Number of use license: SYXK 2014-0023.
3) The method comprises the following steps: 72 mice, divided into 6 groups (group A, group B, group C, group D, group E and group F), 12 mice per group.
Establishing a galactose subacute aging model: the daily subcutaneous injection is adopted, and except a normal control group which is injected with the same amount of normal saline every day, other groups are injected with 0.5g/kg of 5 percent D-galactose every day for 6 weeks continuously, so that the condition of intestinal flora imbalance under the state of old people is simulated.
4) Grouping: different test substances were gavaged in groups starting from week 3 of subcutaneous injection of 0.5g/kg of 5% D-galactose, and the gavages were as shown in Table 1:
TABLE 1 Experimental animals group rearing situation
At the end of the experiment, the mouse picks up eyeballs and takes blood, and serum is separated after centrifugation at 4000Xg for 10min and is subpackaged to be at minus 86 ℃ for storage. After blood collection, mice were sacrificed by cervical dislocation, and livers were separated to prepare a 10% homogenate. And centrifuging at 4000Xg for 10min, and taking homogenate supernatant to be tested.
5) Index measurement:
serum and liver indices were measured according to the superoxide dismutase activity (SOD), Malondialdehyde (MDA) content, and glutathione peroxidase activity (GSH-Px) kit instructions, respectively, and the results are shown in tables 2, 3, and 4.
TABLE 2 glutathione peroxidase (GSH-PX) Activity (U) in serum and liver of groups of mice
Note: p <0.05, p < 0.01, compared to the oxidative senescence model group.
According to table 2, the aging model group showed a significant decrease in GSH-Px in liver tissue compared to the normal group, with a very significant difference (. about.p < 0.01). Compared with the aging model group, the GSH-Px activity in the liver of the dose group in the composition is obviously increased and has a very obvious difference (p is less than 0.01), and the GSH-Px activity in the serum of the high dose group in the composition is obviously increased and has a very obvious difference (p is less than 0.01).
The results show that: the medium and high dose composition has good effect in improving GSH-Px activity in serum and liver tissues and effectively enhancing the function of antioxidant capacity of organisms.
Table 3 superoxide dismutase (SOD) activity (U/mg. protein) in serum and liver of each group of mice
Note: p <0.05 compared to the oxidative senescence model group.
According to table 3, compared with the oxidative aging model group, the SOD activity in serum and liver tissues was increased in the normal control group and the 3 dose groups of the composition, and there was no significant dose effect between the 3 dose groups, the medium dose group was more effective in increasing SOD activity in liver tissues, and there was a significant difference (p <0.05) between the oxidative aging model group.
TABLE 4 MDA content (nmol/mL) in serum and liver of mice in each group
Note: p <0.05 compared to the oxidative senescence model group.
According to table 4, the MDA levels in serum and liver tissues were significantly reduced in the different dose groups of the composition compared to the aging model group, with statistically significant differences (p <0.05) for both serum MDA and aging model group. The results show that: the low dose composition is effective in reducing MDA levels in serum and liver tissues.
In conclusion, under the condition of intestinal flora imbalance in the elderly state, the composition provided by the application can improve the activity of glutathione peroxidase and the activity of superoxide dismutase of a host, reduce the content of malondialdehyde, and achieve the purposes of enhancing the antioxidant activity of the intestinal tract and delaying the aging of the intestinal tract.
Test example 3
Analysis of LPS-producing bacteria (gram-negative bacilli) in the gut
1) The substance to be tested: the composition according to example 1 was stored at 4 ℃ until use.
2) Test animals: BALB/c mice, 24-26 g male-female half-and-half body weight, provided by Nanjing university. Number of use license: SYXK 2014-0023.
3) The method comprises the following steps: 48 mice were divided into 4 groups of 12 mice each, and the mice were divided into groups after adaptive feeding. Except for normal control group mice, the gastric antibiotic-metronidazole (10-20mg/mL) simulates an intestinal dysbacteriosis model for 7 days continuously.
4) Grouping: different test substances were given in groups starting from week 2 at the start of gavage for 4 weeks. The grouping results are shown in table 5.
TABLE 5 grouping of experimental animals
Wherein, the equal volume in table 5 means that the dose of the gavage (week 2) A, C group is equal to the dose of the modeling (week 1) A, C group, and the concentration of each metronidazole is the same. At the end of the experiment, mice were sacrificed by cervical dislocation and cecal content was aseptically collected, weighed, and then diluted to 10-fold gradient with 1:50(m/m) sterile physiological saline to prepare homogenate－6The obtained product is spread on a selective medium and cultured for 36h at constant temperature to identify and count the number of colonies (log10CFU/g), and the number is shown in a table 7; meanwhile, isolation culture was performed to obtain single colony samples for biochemical reaction identification, and the results are shown in Table 6.
TABLE 6 isolation and identification of gram-negative bacilli in intestinal tract
As can be seen from Table 6, the normal control group, the intestinal dysbacteriosis model, the negative control group and the composition group all contained gram-negative bacilli.
TABLE 7 detection of gram-negative bacilli in the mouse intestinal tract (log10CFU/g)
According to table 7, the intestinal flora of the model group mice was significantly changed and gram-negative bacilli were significantly increased (p <0.05) compared to the normal control group, indicating that the intestinal dysbacteriosis model of the mice was successfully established. And the number of the intestinal flora of the mice in the composition intervention group is obviously recovered, the number of gram-negative bacilli is obviously reduced, and the difference with the model group has statistical significance (# p < 0.05).
Similar results were obtained with the above test conducted in example 5, which shows that it is also effective in reducing intestinal harmful bacteria (LPS producing bacteria) without the addition of taste-harmonizing adjuvants, to aid in anti-intestinal aging, while preventing intestinal dysbacteriosis.
In conclusion, the composition for resisting intestinal aging and the application thereof can effectively reduce intestinal harmful bacteria (LPS-producing bacteria) so as to assist in resisting intestinal aging and prevent intestinal dysbacteriosis.
The above description is only a preferred embodiment of the present application and is not intended to limit the present application, and various modifications and changes may be made by those skilled in the art. Any modification, equivalent replacement, improvement and the like made within the spirit and principle of the present application shall be included in the protection scope of the present application.
Claims (10)
1. An anti-aging composition for intestinal tract, which is characterized by comprising the following components in percentage by mass:
ellagic acid 5-10%, vitamin B60.001-0.01 percent, 5-10 percent of fruit and vegetable leavening, 10-20 percent of sorbitol, 20-40 percent of oligosaccharide, 5-20 percent of water-soluble dietary fiber and 0-20 percent of auxiliary material.
2. The composition of claim 1, wherein the oligosaccharides comprise at least one of isomaltooligosaccharides, galactooligosaccharides, and stachyose.
3. The composition according to claim 1, wherein the oligosaccharide consists of isomaltooligosaccharide, galactooligosaccharide and stachyose, wherein the isomaltooligosaccharide is added in an amount of 10 to 20% by mass of the composition, the galactooligosaccharide is added in an amount of 5 to 10% by mass of the composition, and the stachyose is added in an amount of 5 to 10% by mass of the composition.
4. The composition according to any one of claims 1-3, wherein the water-soluble dietary fiber comprises at least one of a resistant dextrin and a polydextrose.
5. The composition according to any one of claims 1 to 3, wherein the water-soluble dietary fibers consist of resistant dextrin and polydextrose, wherein the resistant dextrin is added in an amount of 5% to 10% by mass of the composition and the polydextrose is added in an amount of 5% to 10% by mass of the composition.
6. The composition as claimed in any one of claims 1 to 3, wherein the fruit and vegetable fermented product is obtained by mixing papaya, pineapple, corn, soybean, wheat, brown rice and maltodextrin, inoculating yeast, and fermenting.
7. The composition of any one of claims 1 to 3, wherein the ellagic acid is provided by at least one of pomegranate concentrate powder, blackberry concentrate powder, raspberry concentrate powder, and blueberry concentrate powder.
8. The composition of any one of claims 1-3, wherein the excipient comprises at least one of elastin peptide and bird's nest.
9. The composition as claimed in any one of claims 1 to 3, wherein the auxiliary materials comprise elastin peptide and bird's nest, wherein the elastin peptide is added in an amount of 5-10% of the composition by mass, and the bird's nest is added in an amount of 5-15% of the composition by mass.
10. Use of a composition according to any one of claims 1 to 9 in an anti-ageing preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911324100.9A CN110973630A (en) | 2019-12-20 | 2019-12-20 | Composition for resisting intestinal aging and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911324100.9A CN110973630A (en) | 2019-12-20 | 2019-12-20 | Composition for resisting intestinal aging and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110973630A true CN110973630A (en) | 2020-04-10 |
Family
ID=70073443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911324100.9A Pending CN110973630A (en) | 2019-12-20 | 2019-12-20 | Composition for resisting intestinal aging and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110973630A (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004352644A (en) * | 2003-05-29 | 2004-12-16 | Oriza Yuka Kk | Anti-helicobacter pylori composition |
| CN104489646A (en) * | 2014-11-19 | 2015-04-08 | 李雅君 | Fruit and vegetable probiotic tablet and preparation method thereof |
| CN105661245A (en) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | Probiotic type fruit and vegetable enzyme solid drink |
| US20170020999A1 (en) * | 2014-04-04 | 2017-01-26 | Biotechnobel Sa | Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract |
| CN107158231A (en) * | 2017-06-07 | 2017-09-15 | 马凯 | A kind of composition for the probiotics fermention Chinese herbal medicine for preventing and controlling diabetes |
| CN109198356A (en) * | 2018-11-23 | 2019-01-15 | 温友来 | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal |
| CN109998096A (en) * | 2019-03-19 | 2019-07-12 | 理想如米生物科技(深圳)有限公司 | A kind of ferment probiotic powder controlling weight |
-
2019
- 2019-12-20 CN CN201911324100.9A patent/CN110973630A/en active Pending
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2004352644A (en) * | 2003-05-29 | 2004-12-16 | Oriza Yuka Kk | Anti-helicobacter pylori composition |
| US20170020999A1 (en) * | 2014-04-04 | 2017-01-26 | Biotechnobel Sa | Composition for prevention and/or treatment of chronic inflammation and concomitant biofilms in the gastrointestinal tract |
| CN104489646A (en) * | 2014-11-19 | 2015-04-08 | 李雅君 | Fruit and vegetable probiotic tablet and preparation method thereof |
| CN105661245A (en) * | 2016-01-29 | 2016-06-15 | 江苏微康生物科技有限公司 | Probiotic type fruit and vegetable enzyme solid drink |
| CN107158231A (en) * | 2017-06-07 | 2017-09-15 | 马凯 | A kind of composition for the probiotics fermention Chinese herbal medicine for preventing and controlling diabetes |
| CN109198356A (en) * | 2018-11-23 | 2019-01-15 | 温友来 | A kind of solid beverage and preparation method thereof with adjusting function of intestinal canal |
| CN109998096A (en) * | 2019-03-19 | 2019-07-12 | 理想如米生物科技(深圳)有限公司 | A kind of ferment probiotic powder controlling weight |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105146614B (en) | A kind of functional calcium fruit ferment, enzyme beverage and its production method | |
| US6900173B2 (en) | Perioperative multivitamin protein bar for use in preparing an individual for fast surgical recovery | |
| US20040253227A1 (en) | Perioperative multivitamin protein beverage and additive for use in preparing an individual for fast surgical recovery | |
| EP1854469A1 (en) | Fermentation composition having immunomodulating effect | |
| KR101539382B1 (en) | Food composition for improvement of bowel function and relief of constipation | |
| CN109042881B (en) | Sports fermented dairy product and preparation method thereof | |
| CN108244252A (en) | Probiotics multielement protein powder and preparation method thereof | |
| EP3426269A1 (en) | Food compositions for weaning | |
| CN110338402A (en) | A kind of compound probiotic powder and preparation method thereof | |
| US8722614B2 (en) | Adiponectin production enhancer | |
| KR20180036592A (en) | Novel Lactobacillus sakei and compositions comprising the same | |
| CN111771971A (en) | Composition beneficial to regulating intestinal tract, promoting digestion and improving constipation and preparation method thereof | |
| KR20090049604A (en) | Agent for accelerating the increase in and/or preventing the decrease in blood adiponectin level, and visceral fat accumulation inhibitor | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| CN108669563A (en) | A kind of composition, its application and strengthen immunity, the product for improving allergy | |
| WO2019162425A1 (en) | New process of preparation of glycan composition & uses thereof | |
| CN116076728B (en) | Composition for promoting growth of bifidobacteria | |
| CN111065274A (en) | Fermented milk for promoting increase of amino acid concentration in blood | |
| KR102000170B1 (en) | Food compositions for reducing body fat and improving intestinal function | |
| US20230227771A1 (en) | Pre-conditioning of l.reuteri | |
| EP4056052A1 (en) | Gos pre-conditioning l. reuteri and gos in final formulation | |
| CN1602708A (en) | Active bifidobacteria contained milk powder and its preparation method | |
| CN110973630A (en) | Composition for resisting intestinal aging and application thereof | |
| KR20100037309A (en) | Pill type manufacturing method of health supporting food | |
| CN100469253C (en) | Method for preparing tumor mutation-resisting yoghourt with micron ash tree pollen, pine pollen, bee pollen and ganoderma lucidum spore powder |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200410 |
|
| RJ01 | Rejection of invention patent application after publication |